MARKET

RGLS

RGLS

Regulus Therapeu
NASDAQ
7.87
0.00
0.00%
After Hours: 7.84 -0.03 -0.38% 17:40 05/12 EDT
OPEN
7.86
PREV CLOSE
7.87
HIGH
7.90
LOW
7.82
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
8.20
52 WEEK LOW
0.8301
MARKET CAP
521.34M
P/E (TTM)
-9.5661
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (CMPS), Liquidia Technologies (LQDA) and Regulus (RGLS)
TipRanks · 20h ago
Wells Fargo Sticks to Its Hold Rating for Regulus (RGLS)
TipRanks · 20h ago
Analysts Conflicted on These Healthcare Names: Regulus (RGLS), Mirum Pharmaceuticals (MIRM) and Kymera Therapeutics (KYMR)
TipRanks · 21h ago
Cautious Hold Rating on Regulus Amid Merger Uncertainties and Strategic Developments
TipRanks · 21h ago
Weekly Report: what happened at RGLS last week (0505-0509)?
Weekly Report · 21h ago
Cisco, Walmart Set To Report Results As Markets Watch Out For Core CPI
Seeking Alpha · 2d ago
Catalyst Watch: China trade talks, Walmart earnings, and Take-Two on the GTA hot seat
Seeking Alpha · 3d ago
Regulus Therapeutics to be Acquired by Novartis
TipRanks · 4d ago
More
About RGLS
More
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Recently
Symbol
Price
%Change

Webull offers Regulus Therapeutics Inc stock information, including NASDAQ: RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.